HSBC HOLDINGS PLC - ARCUTIS BIOTHERAPEUTICS INC ownership

Quarter-by-quarter ownership
HSBC HOLDINGS PLC ownership history of ARCUTIS BIOTHERAPEUTICS INC
ValueSharesWeighting
Q3 2023$764,295
-44.6%
143,935
-0.6%
0.00%0.0%
Q2 2023$1,380,087
+3.2%
144,815
+19.2%
0.00%
-50.0%
Q1 2023$1,336,885
-28.1%
121,535
-3.4%
0.00%0.0%
Q4 2022$1,860,648
-25.6%
125,821
-3.8%
0.00%
-50.0%
Q3 2022$2,501,000
+5.0%
130,724
+17.0%
0.00%
+33.3%
Q2 2022$2,383,000
+34.4%
111,757
+21.5%
0.00%
+50.0%
Q1 2022$1,773,000
+118.9%
91,988
+166.5%
0.00%
+100.0%
Q4 2021$810,000
+217.6%
34,523
+283.2%
0.00%
Q4 2020$255,0009,0100.00%
Other shareholders
ARCUTIS BIOTHERAPEUTICS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Frazier Life Sciences Management, L.P. 8,434,232$162,443,00013.84%
Bain Capital Life Sciences Investors, LLC 3,979,292$76,641,0007.44%
Pivotal bioVenture Partners Investment Advisor LLC 569,041$10,960,0005.19%
Logos Global Management LP 1,500,000$28,890,0003.75%
Omega Fund Management, LLC 623,836$12,015,0002.46%
Orbimed Advisors 6,073,850$116,982,0001.90%
MPM BioImpact LLC 258,500$4,979,0001.34%
1492 Capital Management LLC 75,192$1,448,0000.77%
SECTORAL ASSET MANAGEMENT INC 219,136$4,221,0000.75%
EcoR1 Capital, LLC 895,503$17,247,0000.54%
View complete list of ARCUTIS BIOTHERAPEUTICS INC shareholders